医学临床研究
醫學臨床研究
의학림상연구
JOURNAL OF CLINICAL RESEARCH
2014年
7期
1303-1305
,共3页
缬氨酸/治疗应用%糖尿病肾病/药物疗法%糖尿病肾病/血液%内皮缩血管肽1/血液%降钙素基因相关肽/血液
纈氨痠/治療應用%糖尿病腎病/藥物療法%糖尿病腎病/血液%內皮縮血管肽1/血液%降鈣素基因相關肽/血液
힐안산/치료응용%당뇨병신병/약물요법%당뇨병신병/혈액%내피축혈관태1/혈액%강개소기인상관태/혈액
Valine/therapeutic use%Diabetic Nephropathies/drug therapy%Diabetic Nephropathies/blood%Endothelin-1/blood%Calcitonin Gene-Related Peptide/blood
【目的】观察氟伐他汀联合缬沙坦治疗糖尿病肾病（DN）患者的临床疗效及对内皮素-1（ET-1）和降钙素基因相关肽（CGRP）的影响。【方法】将70例DN患者随机分为观察组和对照组，每组35例；在常规治疗的基础上，观察组给予氟伐他汀联合缬沙坦治疗，对照组给予缬沙坦治疗；3个月后分析比较两组患者的24 h尿蛋白定量和血中ET-1、CGRP水平、临床总有效率及不良反应发生情况。【结果】两组患者的24 h尿蛋白定量和血中ET-1水平均较治疗前降低，血中CGRP水平均较治疗前升高，差异有统计学意义（ P ＜0．05或 P ＜0．01），且上述指标的改善观察组优于对照组（ P ＜0．05）；观察组的临床总有效率为91．43％，优于对照组的74．29％（ P ＜0．05）；两组不良反应发生率比较差异无统计学意义（ P ＞0．05）。【结论】氟伐他汀联合缬沙坦治疗DN安全有效，其降脂降压外的肾保护作用可能与调节血中ET-1、CGRP水平有关。
【目的】觀察氟伐他汀聯閤纈沙坦治療糖尿病腎病（DN）患者的臨床療效及對內皮素-1（ET-1）和降鈣素基因相關肽（CGRP）的影響。【方法】將70例DN患者隨機分為觀察組和對照組，每組35例；在常規治療的基礎上，觀察組給予氟伐他汀聯閤纈沙坦治療，對照組給予纈沙坦治療；3箇月後分析比較兩組患者的24 h尿蛋白定量和血中ET-1、CGRP水平、臨床總有效率及不良反應髮生情況。【結果】兩組患者的24 h尿蛋白定量和血中ET-1水平均較治療前降低，血中CGRP水平均較治療前升高，差異有統計學意義（ P ＜0．05或 P ＜0．01），且上述指標的改善觀察組優于對照組（ P ＜0．05）；觀察組的臨床總有效率為91．43％，優于對照組的74．29％（ P ＜0．05）；兩組不良反應髮生率比較差異無統計學意義（ P ＞0．05）。【結論】氟伐他汀聯閤纈沙坦治療DN安全有效，其降脂降壓外的腎保護作用可能與調節血中ET-1、CGRP水平有關。
【목적】관찰불벌타정연합힐사탄치료당뇨병신병（DN）환자적림상료효급대내피소-1（ET-1）화강개소기인상관태（CGRP）적영향。【방법】장70례DN환자수궤분위관찰조화대조조，매조35례；재상규치료적기출상，관찰조급여불벌타정연합힐사탄치료，대조조급여힐사탄치료；3개월후분석비교량조환자적24 h뇨단백정량화혈중ET-1、CGRP수평、림상총유효솔급불량반응발생정황。【결과】량조환자적24 h뇨단백정량화혈중ET-1수평균교치료전강저，혈중CGRP수평균교치료전승고，차이유통계학의의（ P ＜0．05혹 P ＜0．01），차상술지표적개선관찰조우우대조조（ P ＜0．05）；관찰조적림상총유효솔위91．43％，우우대조조적74．29％（ P ＜0．05）；량조불량반응발생솔비교차이무통계학의의（ P ＞0．05）。【결론】불벌타정연합힐사탄치료DN안전유효，기강지강압외적신보호작용가능여조절혈중ET-1、CGRP수평유관。
Objective To observe the clinical efficacy of fluvastatin combined with valsartan for the treatment of pa-tients with diabetic nephropathy (DN) and its impact on endothelial-1(ET-1) and calcitonin gene related peptide(CGRP) .[Methods]Totally 70 patients with DN were randomly divided into observation group and control group with 35 cases in each .On the basis of routine treatment ,the observation group received fluvastatin combined with valsartan ,while the control group received valsartan .The 24h quantitative urinary protein ,blood levels of ET-1 and CGRP ,clinical total effi-cacy and the incidence of adverse reaction were compared between two groups after 3 months .[Results] Compared with before treatment ,the 24h quantitative urinary protein and blood ET-1 in two groups after treatment were decreased ,but blood CGRP was increased ,and there was significant difference ( P<0 .05 or P<0 .01) .The improvement of above in-dexes in observation group was better than the control group ( P<0 .05) .The clinical total effective rate of observation group was better than that of the control group (91 .43% vs .74 .29% )( P<0 .05) .There was no significant difference in the incidence of adverse reactions between two groups ( P >0 .05) .[Conclusion]Fluvastatin combined with valsartan for the treatment of DN is safe and effective .The renal protective effect except lowing blood fat and blood pressure may be related to the regulation of ET-1 and CGRP in blood .
